PMID- 27466726
OWN - NLM
STAT- MEDLINE
DCOM- 20170720
LR  - 20181202
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 28
IP  - 5
DP  - 2016 Sep
TI  - Update on enthesitis-related arthritis.
PG  - 530-6
LID - 10.1097/BOR.0000000000000313 [doi]
AB  - PURPOSE OF REVIEW: This review provides a detailed update regarding the genetics, 
      pathogenesis, disease phenotype evaluation, therapies and expected outcomes for 
      children with enthesitis-related arthritis (ERA). RECENT FINDINGS: Recent studies 
      evaluated human leukocyte antigen (HLA)-B27 subtypes and non-major 
      histocompatibility complex genes including toll like receptor 4, NLRP3, CXCR4 and 
      PTPN12 in children with ERA. The microbiome and gammadelta-T cells have also been an area 
      of active investigation. Several studies focus on the imaging phenotype of 
      children with ERA, including the use of ultrasonography and MRI. MRI techniques 
      studied in this population include dedicated MRI, whole-body MRI and 
      diffusion-weighted imaging. Conventional and biologic disease-modifying agents 
      continue to be the mainstay of therapy, though the past 2 years have witnessed 
      several greatly needed randomized controlled trials to study the efficacy of 
      these medications in ERA. Finally, long-term effectiveness studies of biologics 
      in children with ERA have helped inform provider and patient expectations of 
      disease response and prognosis. SUMMARY: Further evaluation of the role of the 
      microbiome and the interleukin 17/interleukin 23 axis, techniques to optimize 
      evaluation of disease features, and efficacy and effectiveness of newer 
      medications are greatly needed in this understudied population of children.
FAU - Weiss, Pamela F
AU  - Weiss PF
AD  - aDivision of Rheumatology, The Children's Hospital of PhiladelphiabDepartment of 
      Pediatrics, Perelman School of Medicine, University of Pennsylvania, 
      Pennsylvania, Philadelphia, USA.
LA  - eng
GR  - K23 AR059749/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (CXCR4 protein, human)
RN  - 0 (HLA-B27 Antigen)
RN  - 0 (NLR Family, Pyrin Domain-Containing 3 Protein)
RN  - 0 (NLRP3 protein, human)
RN  - 0 (Receptors, Antigen, T-Cell, gamma-delta)
RN  - 0 (Receptors, CXCR4)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 4)
RN  - EC 3.1.3.48 (PTPN12 protein, human)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 12)
SB  - IM
MH  - Adolescent
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Juvenile/diagnostic imaging/drug therapy/genetics/*immunology
MH  - Biological Products/therapeutic use
MH  - Child
MH  - Diffusion Magnetic Resonance Imaging
MH  - Gastrointestinal Microbiome/*immunology
MH  - HLA-B27 Antigen/genetics
MH  - Humans
MH  - Immunity, Humoral/*immunology
MH  - Magnetic Resonance Imaging
MH  - NLR Family, Pyrin Domain-Containing 3 Protein/genetics
MH  - Phenotype
MH  - Prognosis
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 12/genetics
MH  - Receptors, Antigen, T-Cell, gamma-delta/immunology
MH  - Receptors, CXCR4/genetics
MH  - T-Lymphocytes/*immunology
MH  - Toll-Like Receptor 4/genetics
MH  - Ultrasonography
EDAT- 2016/07/29 06:00
MHDA- 2017/07/21 06:00
CRDT- 2016/07/29 06:00
PHST- 2016/07/29 06:00 [entrez]
PHST- 2016/07/29 06:00 [pubmed]
PHST- 2017/07/21 06:00 [medline]
AID - 00002281-201609000-00011 [pii]
AID - 10.1097/BOR.0000000000000313 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2016 Sep;28(5):530-6. doi: 10.1097/BOR.0000000000000313.